Cargando…
Retinoic Acid Receptor Is a Novel Therapeutic Target for Postoperative Cognitive Dysfunction
Postoperative cognitive dysfunction (POCD) is a clinical syndrome characterizing by cognitive impairments in the elderly after surgery. There is limited effective treatment available or clear pathological mechanisms known for this syndrome. In this study, a Connectivity Map (CMap) bioinformatics mod...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538227/ https://www.ncbi.nlm.nih.gov/pubmed/37765280 http://dx.doi.org/10.3390/pharmaceutics15092311 |
_version_ | 1785113278347739136 |
---|---|
author | Bao, Yongjie Rong, Wenni Zhu, An Chen, Yuan Chen, Huiyue Hong, Yirui Le, Jingyang Wang, Qiyao Naman, C. Benjamin Xu, Zhipeng Liu, Lin Cui, Wei Wu, Xiang |
author_facet | Bao, Yongjie Rong, Wenni Zhu, An Chen, Yuan Chen, Huiyue Hong, Yirui Le, Jingyang Wang, Qiyao Naman, C. Benjamin Xu, Zhipeng Liu, Lin Cui, Wei Wu, Xiang |
author_sort | Bao, Yongjie |
collection | PubMed |
description | Postoperative cognitive dysfunction (POCD) is a clinical syndrome characterizing by cognitive impairments in the elderly after surgery. There is limited effective treatment available or clear pathological mechanisms known for this syndrome. In this study, a Connectivity Map (CMap) bioinformatics model of POCD was established by using differently expressed landmark genes in the serum samples of POCD and non-POCD patients from the only human transcriptome study. The predictability and reliability of this model were further supported by the positive CMap scores of known POCD inducers and the negative CMap scores of anti-POCD drug candidates. Most retinoic acid receptor (RAR) agonists were negatively associated with POCD in this CMap model, suggesting that RAR might be a novel target for POCD. Most importantly, acitretin, a clinically used RAR agonist, significantly inhibited surgery-induced cognitive impairments and prevented the reduction in RARα and RARα-target genes in the hippocampal regions of aged mice. The study denotes a reliable CMap bioinformatics model of POCD for future use and establishes that RAR is a novel therapeutic target for treating this clinical syndrome. |
format | Online Article Text |
id | pubmed-10538227 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105382272023-09-29 Retinoic Acid Receptor Is a Novel Therapeutic Target for Postoperative Cognitive Dysfunction Bao, Yongjie Rong, Wenni Zhu, An Chen, Yuan Chen, Huiyue Hong, Yirui Le, Jingyang Wang, Qiyao Naman, C. Benjamin Xu, Zhipeng Liu, Lin Cui, Wei Wu, Xiang Pharmaceutics Article Postoperative cognitive dysfunction (POCD) is a clinical syndrome characterizing by cognitive impairments in the elderly after surgery. There is limited effective treatment available or clear pathological mechanisms known for this syndrome. In this study, a Connectivity Map (CMap) bioinformatics model of POCD was established by using differently expressed landmark genes in the serum samples of POCD and non-POCD patients from the only human transcriptome study. The predictability and reliability of this model were further supported by the positive CMap scores of known POCD inducers and the negative CMap scores of anti-POCD drug candidates. Most retinoic acid receptor (RAR) agonists were negatively associated with POCD in this CMap model, suggesting that RAR might be a novel target for POCD. Most importantly, acitretin, a clinically used RAR agonist, significantly inhibited surgery-induced cognitive impairments and prevented the reduction in RARα and RARα-target genes in the hippocampal regions of aged mice. The study denotes a reliable CMap bioinformatics model of POCD for future use and establishes that RAR is a novel therapeutic target for treating this clinical syndrome. MDPI 2023-09-13 /pmc/articles/PMC10538227/ /pubmed/37765280 http://dx.doi.org/10.3390/pharmaceutics15092311 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bao, Yongjie Rong, Wenni Zhu, An Chen, Yuan Chen, Huiyue Hong, Yirui Le, Jingyang Wang, Qiyao Naman, C. Benjamin Xu, Zhipeng Liu, Lin Cui, Wei Wu, Xiang Retinoic Acid Receptor Is a Novel Therapeutic Target for Postoperative Cognitive Dysfunction |
title | Retinoic Acid Receptor Is a Novel Therapeutic Target for Postoperative Cognitive Dysfunction |
title_full | Retinoic Acid Receptor Is a Novel Therapeutic Target for Postoperative Cognitive Dysfunction |
title_fullStr | Retinoic Acid Receptor Is a Novel Therapeutic Target for Postoperative Cognitive Dysfunction |
title_full_unstemmed | Retinoic Acid Receptor Is a Novel Therapeutic Target for Postoperative Cognitive Dysfunction |
title_short | Retinoic Acid Receptor Is a Novel Therapeutic Target for Postoperative Cognitive Dysfunction |
title_sort | retinoic acid receptor is a novel therapeutic target for postoperative cognitive dysfunction |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538227/ https://www.ncbi.nlm.nih.gov/pubmed/37765280 http://dx.doi.org/10.3390/pharmaceutics15092311 |
work_keys_str_mv | AT baoyongjie retinoicacidreceptorisanoveltherapeutictargetforpostoperativecognitivedysfunction AT rongwenni retinoicacidreceptorisanoveltherapeutictargetforpostoperativecognitivedysfunction AT zhuan retinoicacidreceptorisanoveltherapeutictargetforpostoperativecognitivedysfunction AT chenyuan retinoicacidreceptorisanoveltherapeutictargetforpostoperativecognitivedysfunction AT chenhuiyue retinoicacidreceptorisanoveltherapeutictargetforpostoperativecognitivedysfunction AT hongyirui retinoicacidreceptorisanoveltherapeutictargetforpostoperativecognitivedysfunction AT lejingyang retinoicacidreceptorisanoveltherapeutictargetforpostoperativecognitivedysfunction AT wangqiyao retinoicacidreceptorisanoveltherapeutictargetforpostoperativecognitivedysfunction AT namancbenjamin retinoicacidreceptorisanoveltherapeutictargetforpostoperativecognitivedysfunction AT xuzhipeng retinoicacidreceptorisanoveltherapeutictargetforpostoperativecognitivedysfunction AT liulin retinoicacidreceptorisanoveltherapeutictargetforpostoperativecognitivedysfunction AT cuiwei retinoicacidreceptorisanoveltherapeutictargetforpostoperativecognitivedysfunction AT wuxiang retinoicacidreceptorisanoveltherapeutictargetforpostoperativecognitivedysfunction |